Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499315 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02499315 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 32 participants.
The verdict
NCT02499315, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of the study is to find out if AMG 357 is safe and tolerated by women with Rhematoid Arthritis.
Interventions
- DRUG Placebo
- DRUG AMG 357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499315
The ClinicalTrials.gov registry entry for NCT02499315 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02499315 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499315 about?
NCT02499315 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis". The purpose of the study is to find out if AMG 357 is safe and tolerated by women with Rhematoid Arthritis.
What is the current status of trial NCT02499315?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-04. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02499315?
The interventions under investigation include: Placebo (DRUG), AMG 357 (DRUG).
Who is sponsoring clinical trial NCT02499315?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.